As Sanofi's Pompe drug shortage drags on, some patients struggle to access treatments
Sanofi’s Pompe treatments, Lumizyme and Nexviazyme, have been in short supply for more than three months. Patients who depend on regular infusions have learned that appointments may be canceled. The disruption matters because these medicines replace an enzyme that Pompe patients lack and help protect their muscles. Monique Griffin, who has Pompe disease, received an email saying a shipping delay interrupted her supply and canceled her next infusion. Sanofi says it has made progress restoring supply to patients in some countries. But the company warned that shipping delays could interrupt infusions for some U.S. patients through the end of November. Sanofi attributes the shortage to issues at its manufacturing facility in Ireland, including work to address FDA concerns. The company says there are no drug-quality issues and that it is prioritizing the most vulnerable patients. It advises patients to consult a health professional before considering another treatment, because the medicines are not interchangeable.
What has happened to the supply of Sanofi’s Pompe treatments, and how long could some U.S. patients face delays?
Sanofi’s Pompe treatments, Lumizyme and Nexviazyme, have been in short supply for more than three months. Patients who depend on regular infusions have learned that appointments may be canceled. The disruption matters because these medicines replace an enzyme that Pompe patients lack and help protect their muscles.
Monique Griffin, who has Pompe disease, received an email saying a shipping delay interrupted her supply and canceled her next infusion. Sanofi says it has made progress restoring supply to patients in some countries. But the company warned that shipping delays could interrupt infusions for some U.S. patients through the end of November.
Sanofi attributes the shortage to issues at its manufacturing facility in Ireland, including work to address FDA concerns. The company says there are no drug-quality issues and that it is prioritizing the most vulnerable patients. It advises patients to consult a health professional before considering another treatment, because the medicines are not interchangeable.
What can happen to a patient’s health when a Pompe infusion is delayed or missed?
Pompe disease causes glycogen, a complex sugar, to build up inside cells because patients lack an enzyme needed to break it down. The buildup weakens muscles and can enlarge the heart. The disease can also make breathing and eating difficult, and it is often fatal if untreated.
The article describes the stakes for patients who rely on infusions every two weeks. Monique Griffin says a canceled infusion feels like letting the disease take over again. Chelsey McGee worries that missing even one appointment could damage her 10-year-old son Logan’s heart. Sanofi’s treatment has helped him stay healthy enough to play soccer.
The article does not say that every delayed or missed infusion will cause a specific harm, or how quickly health might change. It does show why patients are anxious: treatment is intended to protect muscles, and families depend on regular access. Griffin has previously missed a few appointments, but the article’s final account of that experience is incomplete.
What is Pompe disease, and what does it do to the body?
Pompe disease is a rare muscle-wasting condition named after the Dutch pathologist who discovered it nearly a century ago. People with the disease lack an enzyme that breaks down a complex sugar called glycogen. Without that enzyme, glycogen builds up inside their cells.
The buildup harms the body’s muscles. The article says patients’ muscles weaken and their hearts can become enlarged. They may also have trouble breathing and eating. The article describes the condition as often fatal when left untreated, showing why continuing care matters to patients and families.
Sanofi’s Lumizyme and Nexviazyme are enzyme replacement treatments: they provide the missing enzyme and help protect patients’ muscles. Patients typically receive the drugs every two weeks. A supply disruption has meant some infusions were canceled or could be interrupted, raising concern among patients who rely on the treatment. Other Pompe treatments are in clinical trials, including gene therapies from AskBio and Astellas Pharma.
How rare is Pompe disease, and how often do patients typically need treatment?
Pompe disease is rare: the article says about one in every 19,000 babies is born with it. The condition is named after the Dutch pathologist who discovered it nearly a century ago. Even though it is uncommon, patients depend on ongoing care because the disease can weaken muscles and affect the heart, breathing, and eating.
Sanofi’s Lumizyme and Nexviazyme replace the enzyme that Pompe patients lack, helping protect their muscles. Patients typically receive the drugs every two weeks. That schedule makes reliable supply important: a disruption can mean a canceled or interrupted infusion for someone who relies on treatment.
The article reports that supply problems have continued for more than three months. Sanofi says it has restored supply for patients in some countries, but shipping delays could interrupt infusions for some U.S. patients through the end of November. Several other Pompe treatments, including gene therapies from AskBio and Astellas Pharma, have entered clinical trials; the article does not say they are available as replacements.
Why can’t patients simply switch to another medicine when Lumizyme or Nexviazyme is unavailable?
The article’s direct answer is that Sanofi’s medicines are “not interchangeable.” The company says patients should speak with a health professional before taking another treatment. That guidance matters during a shortage because an unavailable infusion may leave patients and families looking for another option, but the company warns against making that change on their own.
Lumizyme and Nexviazyme are both Sanofi treatments that replace the missing enzyme in Pompe disease and help protect patients’ muscles. The article does not explain whether their formulations, doses, or effects differ, so it does not support a more specific explanation for why they are not interchangeable. It also does not say that patients should switch to another medicine.
Several other Pompe treatments have entered clinical trials, including separate gene therapies from AskBio and Astellas Pharma. The article presents these as treatments being tested, not as ready alternatives for patients whose infusions are disrupted. For now, Sanofi’s advice is to consult a health professional before considering another treatment.
How did problems at Sanofi’s Irish manufacturing facility contribute to the treatment shortage?
Sanofi says the Pompe treatment shortage stems from issues at its manufacturing facility in Ireland. Public documents show the company had known about manufacturing concerns for several months. Addressing the FDA’s ongoing concerns contributed to the supply disruption, according to Sanofi.
The FDA inspected the plant from January 12 to January 20, 2026, and found violations involving two unrelated drugs. Sanofi began responding to the violations in February. On June 22, the FDA sent the company a warning letter saying it still had not addressed the “underlying failure” to comply with manufacturing requirements.
Sanofi says there were no issues with drug quality, while also saying the manufacturing concerns contributed to disrupted supply. It has made progress restoring treatment supply in some countries, but shipping delays could interrupt some U.S. patients’ infusions through the end of November. The company says it is working to stabilize supply and prioritizing the most vulnerable patients.
How does enzyme replacement therapy help the body break down glycogen in Pompe disease?
In Pompe disease, patients lack an enzyme that breaks down glycogen, a complex sugar. Without enough of that enzyme, glycogen builds up inside cells. The buildup weakens muscles and can affect the heart, breathing, and eating. The disease is often fatal if untreated.
Enzyme replacement therapy works by supplying the enzyme patients are missing. The article says Sanofi’s Lumizyme and Nexviazyme replace that enzyme and protect patients’ muscles. Patients typically receive the medicines every two weeks, making continued access important for those who rely on them.
A shortage of Sanofi’s treatments has led to canceled infusions and could interrupt some U.S. patients’ care through the end of November. Sanofi says it is working to stabilize supply and has restored it for patients in some countries. The company also advises patients to speak with a health professional before taking another treatment, because these medicines are not interchangeable.
This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.
Read more in the JupiteX app
Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.
Or read more news on the web